G0S2 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistently, treatment of BP‐CML cell lines and primary cells with the DNA methyltransferase inhibitor, 5‐azacytidine, increased G0S2 mRNA expression (Figure S2).